Physician profile
Steven Michael Cantrell
NPI 1861431413
$2,556.64
in general payments reported to CMS, 2019-2025
17 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $37.66 · 2021: $23.68 · 2022: $170 · 2023: $662 · 2024: $494 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $409.69 | 2021-2024 | Kxl System (Not Refurbished), Photrexa Cross-Linking Kit, Ce-Marked Kxla System |
| Carl Zeiss Meditec, INC. | $321.99 | 2019 | |
| Rxsight INC | $287.50 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $247.55 | 2025 | Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $230.35 | 2023-2024 | Acuvue |
| Sight Sciences, INC. | $210.58 | 2022-2024 | Omni Surgical System |
| Omeros Corporation | $180.12 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $145.42 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $124.07 | 2019 | |
| Abbvie INC. | $118.00 | 2023 | Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.19 | 2019 | |
| Genentech USA, INC. | $46.80 | 2022 | |
| Allergan, INC. | $37.66 | 2020 | |
| Alcon Vision LLC | $34.25 | 2024-2025 | Clareon |
| Thea Pharma INC. | $16.84 | 2025 | Iyuzeh |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $14.40 | 2022 | |
| Horizon Therapeutics Plc | $14.23 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Cantrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.